Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.


Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Anti-SARS-CoV-2 Antibody Products

Last Updated: February 11, 2021

Summary Recommendations
Summary Recommendations
  • There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of the following products for the treatment of COVID-19:
    • COVID-19 convalescent plasma
      • The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for hospitalized patients with COVID-19 (see Convalescent Plasma for more details).
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins
  • There are currently insufficient data for the Panel to recommend either for or against the use of the following anti-SARS-CoV-2 monoclonal antibodies for the treatment of nonhospitalized patients with mild to moderate COVID-19:
    • Bamlanivimab
    • The combination of casirivimab plus imdevimab
      • The FDA has issued EUAs for the use of bamlanivimab and the casirivimab plus imdevimab combination for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression (see Anti-SARS-CoV-2 Monoclonal Antibodies for more details).
  • The FDA also recently issued an EUA for bamlanivimab plus etesevimab for the treatment of certain nonhospitalized patients with mild to moderate COVID-19; the Panel will issue recommendations on the use of this combination shortly.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion